Company · founded 1996
Simulations Plus (United States)
Lancaster, United States · simulations-plus.com
- Citations, last 5 years
- 1 302
- Works, last 5 years
- 209
- h-index
- 58
- Scientists listed
- 0
- Grants since 2016
- 18
Grants received
2024–2027 · cooperative agreement · U01
From Bench to Bioequivalence: In Vitro Mechanistic Understanding of ASD Drug Products in Simulated Gastrointestinal Conditions
Maxime Le Merdy · Simulations Plus (United States) · funded by U.S. Food and Drug Administration
2024–2025 · research · R43
Improving Similarity Scoring in Drug Discovery: Solving by Solvating
Jeremy O Jones · Simulations Plus (United States) · funded by National Institutes of Health
2024–2027 · cooperative agreement · U01
From Bench to Bioequivalence: In Vitro Mechanistic Understanding of ASD Drug Products in Simulated Gastrointestinal Conditions
Maxime Le Merdy · Simulations Plus (United States) · funded by U.S. Food and Drug Administration
2023–2025 · cooperative agreement · U01
Development and validation of a workflow to conduct virtual bioequivalence studies using PBBM-PBPK models
Frederico Severino Martins · Simulations Plus (United States) · funded by U.S. Food and Drug Administration
2023–2026 · cooperative agreement · U01
Development and validation of a workflow to conduct virtual bioequivalence studies using PBBM-PBPK models
Frederico Severino Martins · Simulations Plus (United States) · funded by U.S. Food and Drug Administration
2021–2024 · research · R44
Software for predicting liver injury from biologics drug candidates using data from a human liver microphysiology system
Kyunghee Yang · Simulations Plus (United States) · funded by National Institutes of Health
2021–2022 · research · R43
Software for Predicting Liver Injury from Biologics Drug Candidates Using Data from a Human Liver Microphysiology System
Brett Alyn Howell · Simulations Plus (United States) · funded by National Institutes of Health
2021–2023 · cooperative agreement · U01
Dermal Drug Product Quality and Bioequivalence Assessment through Advanced MAM and PBPK Simulation
Manas Shah · Simulations Plus (United States) · funded by U.S. Food and Drug Administration
2021–2025 · research · R44
Software for predicting liver injury from biologics drug candidates using data from a human liver microphysiology system
Kyunghee Yang · Simulations Plus (United States) · funded by National Institutes of Health
2021–2024 · cooperative agreement · U01
Dermal Drug Product Quality and Bioequivalence Assessment through Advanced MAM and PBPK Simulation
Manas Shah · Simulations Plus (United States) · funded by U.S. Food and Drug Administration
2020–2023 · cooperative agreement · U01
Development and Validation of a PBPK/PD Modeling Strategy for Ophthalmic Drug Products to Support Translation from Preclinical Species to Human
Jessica Rose Spires · Simulations Plus (United States) · funded by U.S. Food and Drug Administration
2020–2024 · cooperative agreement · U01
Development and Validation of a PBPK/PD Modeling Strategy for Ophthalmic Drug Products to Support Translation from Preclinical Species to Human
Jessica Rose Spires · Simulations Plus (United States) · funded by U.S. Food and Drug Administration
2020–2024 · cooperative agreement · U01
Development and Validation of a PBPK/PD Modeling Strategy for Ophthalmic Drug Products to Support Translation from Preclinical Species to Human
Jessica Rose Spires · Simulations Plus (United States) · funded by U.S. Food and Drug Administration
2020–2023 · cooperative agreement · U01
Development and Validation of a PBPK/PD Modeling Strategy for Ophthalmic Drug Products to Support Translation from Preclinical Species to Human
Jessica Rose Spires · Simulations Plus (United States) · funded by U.S. Food and Drug Administration
2018–2020 · grant · Standard Grant
SBIR Phase II: Automating the Design of Photonic Devices using Cloud-Based Computational Electromagnetics
Ardavan Oskooi · Simulations Plus (United States) · funded by National Science Foundation
2018–2020 · cooperative agreement · U01
Assessment of Transdermal Drug Product Quality and Performance Attributes via Enhanced Virtual Bioequivalence Simulations
Jessica Rose Spires · Simulations Plus (United States) · funded by U.S. Food and Drug Administration
2018–2021 · cooperative agreement · U01
Assessment of Transdermal Drug Product Quality and Performance Attributes via Enhanced Virtual Bioequivalence Simulations
Jessica Rose Spires · Simulations Plus (United States) · funded by U.S. Food and Drug Administration
2016–2018 · grant · Standard Grant
SBIR Phase I: Automating the Design of Photonic Devices using Cloud-Based Computational Electromagnetics
Ardavan Oskooi · Simulations Plus (United States) · funded by National Science Foundation